What Is Tesamorelin?

Tesamorelin is a growth hormone–releasing hormone (GHRH) analog. FDA-approved tesamorelin products are indicated for reducing excess abdominal fat in adults with HIV and lipodystrophy. Outside that specific approved context, tesamorelin is framed as clinician-reviewed and is not implied to be FDA-approved for general fat loss, bodybuilding, anti-aging, or wellness.

How It Works

Tesamorelin stimulates pituitary growth hormone release through the GHRH receptor, which can increase IGF-1. In its approved context, it is used to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not the same as directly administering growth hormone.

What It’s Studied For

Tesamorelin is supported by FDA labeling for HIV-associated lipodystrophy. It has been studied for visceral adipose tissue reduction, effects on IGF-1, glucose-related considerations, and safety concerns such as fluid retention and neoplasm risk considerations.

How It May Be Used in a Clinician-Supervised Program

A licensed clinician may consider tesamorelin only after reviewing goals, metabolic status, HIV/lipodystrophy context if relevant, glucose/diabetes risk, malignancy history, IGF-1 levels or concerns, pregnancy status, and medication list. It is not sold as a simple weight-loss injection.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• Increased risk of neoplasms and elevated IGF-1.
• Fluid retention, glucose intolerance or diabetes mellitus, hypersensitivity, and injection-site reactions.
• Contraindication in pregnancy for the labeled product context.
• Active malignancy, pregnancy, uncontrolled diabetes, or significant fluid retention require careful review.

Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.

Frequently Asked Questions